Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited has decided to withdraw its application for marketing approval of the SPL7013 Nasal Spray in Australia after a lengthy review process. The company aims to focus on its core strategic priorities, including its DEP technology platform, while continuing to market the nasal spray in other regions like the UK and Europe. This move aligns with Starpharma’s broader plan to enhance long-term sustainability and shareholder value.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
